Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05831111 · ClinicalTrials.gov registry record · Phase 1

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

A Phase 1 study of Epstein-Barr Virus Infection, sponsored by ModernaTX.

Active
Registry status
Phase 1
Development phase
482
Enrollment target
20
Study locations

NCT05831111: Active Phase 1 study of Epstein-Barr Virus Infection, sponsored by ModernaTX.

NCT05831111 is a Phase 1 study of Epstein-Barr Virus Infection that is active but no longer recruiting, run by ModernaTX. The registered enrollment target is 482 participants, above the 404-participant average among 6 other Epstein-Barr Virus Infection trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05831111, a Phase 1 study of Epstein-Barr Virus Infection, is active but no longer recruiting, sponsored by ModernaTX.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
482 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

Interventions

  • BIOLOGICAL Placebo
  • BIOLOGICAL mRNA-1195
  • BIOLOGICAL mRNA-1195.1
  • BIOLOGICAL mRNA-1195.2
  • BIOLOGICAL mRNA-1189

Study Locations (20)

Nebraska

  • Velocity Clinical Research - Grand Island
  • Velocity Clinical Research - Hastings
  • Velocity Clinical Research - Lincoln
  • Velocity Clinical Research - Norfolk
  • Velocity Clinical Research - Omaha

Illinois

  • Optimal Research - Peoria
  • DM Clinical Research- River Forest - River Forest

Massachusetts

  • DM Clinical Research - Brookline
  • University of Massachusetts Chan Medical School - Worcester

Alabama

  • Pinnacle Research Group, LLC - Anniston

Arizona

  • Noble Clinical Research - Tucson

California

  • Marvel Clinical Research - Huntington Beach

Colorado

  • Tekton Research - Longmont

Florida

  • Suncoast Research Group, LLC - Miami

Trial Details

FieldValue
Enrollment Target 482 participants
Start Date 2023-04-05
Est. Completion 2026-10-07
Phase Phase 1
ModernaTX

90 total trials

What the registry record for NCT05831111 still lists

NCT05831111 is an interventional study that assigns participants to a tested intervention. The registered 482 participants enrollment target is mid-sized for trials with a published cap, above the 404-participant average among 6 other Epstein-Barr Virus Infection trials with a reported enrollment target (19% higher).

The record links to 1 condition, with Epstein-Barr Virus Infection appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT05831111 names 20 study sites across 14 states, led by Nebraska, Illinois, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05831111 about?

NCT05831111 is a clinical study titled "A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants". The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy participants.

What is the current status of trial NCT05831111?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 482 participants. The study started on 2023-04-05. Estimated completion is 2026-10-07.

What conditions does trial NCT05831111 study?

This clinical trial studies the following conditions: Epstein-Barr Virus Infection.

What interventions are being tested in trial NCT05831111?

The interventions under investigation include: Placebo (BIOLOGICAL), mRNA-1195 (BIOLOGICAL), mRNA-1195.1 (BIOLOGICAL), mRNA-1195.2 (BIOLOGICAL), mRNA-1189 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05831111?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05831111 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Epstein-Barr Virus Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04449458 · 482 participants · NA

    The Positively Quit Trial for Smoking Cessation

  • NCT07079631 · 482 participants · Phase 1

    A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

  • NCT02871726 · 483 participants · NA

    Transrectal Ultrasound Robot-Assisted Prostate Biopsy

  • NCT05421741 · 484 participants · Phase 4

    Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05831111, the US trial registry maintained by the National Library of Medicine. NCT05831111 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.